...
...
Next Story

Covid-19 vaccine update: Russia begins clinical trials, Gilead to enrol pediatric patients in remdesivir testing

From experimental drug remdesivir making strides to generic steroid drug dexamethasone emerging as the first Covid-19 drug, the race to developing the antidote to Covid-19 is getting more interesting by the day.

Updated on: Jun 18, 2020, 12:49:29 IST
Hindustan Times, New Delhio | By
Prefer HTon Google
Advertisement

With global coronavirus cases crossing the 8 million-mark, the need for an anti-Covid-19 vaccine becomes more urgent. Drug-makers and experts across the world are ramping up efforts to arrive at the potential vaccine against Covid-19.

File photo: A researcher at Protein Sciences reaches for a vial in a lab in Meriden, Conn. The biotech company is currently researching a vaccine for Covid-19. (AP)
File photo: A researcher at Protein Sciences reaches for a vial in a lab in Meriden, Conn. The biotech company is currently researching a vaccine for Covid-19. (AP)

From experimental drug remdesivir making strides to generic steroid drug dexamethasone emerging as the first Covid-19 drug, the race to developing the antidote to Covid-19 is getting more interesting by the day.

Here are some of the latest development around Covid-19 vaccine development:

• Drugmaker Gilead Sciences said it will soon begin enrolment of pediatric patients with moderate-to-severe Covid-19 in a late-stage study testing its experimental drug, remdesivir.

• Clinical trials of a Russian coronavirus vaccine started on Wednesday, the Health Ministry said in a statement.

• The European Union (EU) is planning to accelerate the development of Covid-19 vaccines through advance purchase agreements with promising medical companies, the bloc announced in a statement on Wednesday.

Also read: ‘Covid-19 an opportunity, taught India to become self-reliant’ - PM Modi

• The WHO said testing of the malaria drug hydroxychloroquine in its large multi-country trial of treatments for Covid-19 patients had been halted after results from other trials showed no benefit.

• China National Pharmaceutical Group Corp. known as Sinopharm on Tuesday said that an inactivated Covid-19 vaccine developed by its subsidiary China National Biotec Group’s (CNBG) Wuhan Institute of Biological Products has triggered a strong neutralizing antibody response in a phase 1/2 trial.

 
Get the latest World News, breaking headlines and global updates from the US, UK, Pakistan, Bangladesh, Russia and other countries. Follow major international events on Hindustan Times.
Get the latest World News, breaking headlines and global updates from the US, UK, Pakistan, Bangladesh, Russia and other countries. Follow major international events on Hindustan Times.
SHARE THIS ARTICLE ON
Hindustantimes wants to start sending you push notifications. Click allow to subscribe